Descripción de la empresa
Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical entity focused on the development and potential commercialization of orally bioavailable small molecule therapeutic products. The company's strategic scope encompasses the treatment of specific medical conditions including cancer, liver inflammatory diseases, and erectile dysfunction within the Israeli market. This specialized focus places the firm squarely within the healthcare sector, specifically the biotechnology industry, where innovation in drug discovery and clinical development are primary drivers of value creation. Currently, the company maintains a market capitalization of $7.11M and reports annual revenue of $405,000, while employing a workforce of 5 individuals. These financial figures indicate that Can-Fite is a micro-cap entity with a very limited revenue base relative to its valuation, suggesting that its current stock price is derived almost exclusively from the potential future value of its pipeline assets rather than established cash flows from sales.
Salud financiera
The company reports trailing twelve-month revenue of $405,000 against a net income of -$9,828,000 and an EBITDA of -$9,926,000. The substantial disparity between the minimal revenue of $405,000 and the significant net loss of -$9,828,000 reveals a cost structure heavily dominated by research and development expenses, clinical trial costs, and general administrative overheads typical of early-stage biotechnology firms. Free cash flow stands at -$4,985,750, indicating that the company is burning through its capital reserves to fund operations and asset development rather than generating positive operating cash flows. This negative free cash flow underscores the company's current lack of financial flexibility and its reliance on external capital sources to sustain its R&D activities. Gross margin is reported at 100.0%, reflecting the nature of the business where revenue is recorded before the deduction of cost of goods sold, often including significant R&D allocations in this stage, while the operating margin of -2488.7% and profit margin of 0.0% highlight the deep structural losses inherent in clinical-stage development. The balance sheet holds $8.54M in cash against only $71,000 in debt, creating a liquidity position that appears robust on a static basis. The debt-to-equity ratio of 1.27 suggests a leveraged capital structure relative to equity, yet the absolute dollar amount of debt is negligible compared to cash reserves. The current ratio of 3.46 indicates strong short-term liquidity, as current assets are more than three times the current liabilities, providing a comfortable buffer against immediate obligations. Return on Equity is -178.2% and return on assets is -66.7%, metrics that demonstrate the company is currently destroying shareholder value in the accounting sense due to the accumulation of losses, which is expected for firms in the clinical-stage where capital expenditures and R&D costs exceed revenue generation.
Evaluación de valoración
The P/E Ratio (TTM) is listed as N/A due to the negative earnings, while the forward P/E is calculated at -4.15. The existence of a negative forward P/E implies that analysts or the market is pricing in future earnings that are expected to turn positive or that the current valuation is based on enterprise value multiples rather than traditional earnings multiples. The price-to-book ratio is 1.42, indicating that the market values the company at a 42% premium over its net asset value, which may reflect intangible value in the drug pipeline or potential off-balance-sheet assets not fully captured in book value. The price-to-sales ratio stands at 17.56, a metric often used for unprofitable biotech firms to gauge the revenue multiple investors are willing to pay for growth potential. The EV/EBITDA multiple is -0.46, which is an unusual negative multiple that typically arises when enterprise value is low or debt is high relative to negative earnings, further emphasizing the speculative nature of the valuation. The stock has a 52-week high of $36.40 and a 52-week low of $2.95. Without the specific current price provided in the data source to calculate the exact percentage, the trading range spans a massive volatility corridor, suggesting the price sits somewhere within a wide band where the lower bound represents a discount of approximately 92% from the high. The beta is -0.10, a highly anomalous value for an equity security that implies the stock price moves inversely to the broader market or that the data source contains an outlier value, as a negative beta of this magnitude suggests extreme idiosyncratic risk or a mechanical data error rather than a standard inverse correlation with the market index.
Growth & Income
Revenue growth year-over-year is reported at -43.3%, while earnings growth is N/A due to the absence of profitable earnings history. The negative revenue growth indicates a contraction in sales, which could stem from the cessation of sales of earlier products or a transition phase where revenue has not yet been established by new clinical candidates. Since the company is not a dividend payer, there is no dividend yield or payout ratio to analyze, meaning the payout ratio is effectively 0.0% as no dividends are distributed to shareholders. In the absence of a dividend program, the company's strategy necessarily involves reinvesting its remaining capital and any future earnings back into the company to fund ongoing clinical trials and product development efforts. The overall growth and income profile is characterized by significant revenue contraction and a lack of current profitability, relying entirely on the potential future success of its lead drug candidate Piclidenoson to drive future value appreciation for shareholders.